Chronic Intravascular Coagulation Syndrome
- 11 April 1968
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 278 (15), 815-821
- https://doi.org/10.1056/nejm196804112781503
Abstract
In a patient with a chronic intravascular coagulation syndrome characterized by depletion of fibrinogen and platelets, participation of other clotting factors or secondary fibrinolysis were not demonstrable. Heparin was effective in controlling the syndrome, which was evident 10 months before discovery of a primary ovarian carcinoma. Warfarin did not prevent thrombotic complications.This publication has 41 references indexed in Scilit:
- The Symptomatic Effect of Anticoagulant Therapy in Defibrination Syndrome Associated with Demonstrable Fibrin in Plasma A Case ReportActa Medica Scandinavica, 2009
- The clinical usage of heparinThe American Journal of Cardiology, 1964
- Clinical experiences of a surgeon in the use of heparinThe American Journal of Cardiology, 1964
- HEPARIN TREATMENT OF BLEEDINGThe Lancet, 1963
- PATHOGENESIS OF THE COAGULATION DEFECT DEVELOPING DURING PATHOLOGICAL PLASMA PROTEOLYTIC (“FIBRINOLYTIC”) STATES. I. THE SIGNIFICANCE OF FIBRINOGEN PROTEOLYSIS AND CIRCULATING FIBRINOGEN BREAKDOWN PRODUCTS*Journal of Clinical Investigation, 1962
- A Heparin-Precipitable Fraction of Human Plasma. I. Isolation and Characterization of the Fraction1Journal of Clinical Investigation, 1957
- Interference of abnormal plasma proteins with the clotting mechanismAmerican Journal Of Medicine, 1957
- The Non-clotting Component of the Human Plasma Fraction I-1 (“Cold Insoluble Globulin”)1Journal of the American Chemical Society, 1955
- ALOPECIA AND OTHER TOXIC EFFECTS OF HEPARIN AND SYNTHETIC HEPARINOIDSThe American Journal of the Medical Sciences, 1954
- Preparation and Properties of Serum and Plasma Proteins. XVIII. The Separation of Purified Fibrinogen from Fraction I of Human Plasma.Journal of the American Chemical Society, 1948